Isomorphic Labs raises $5 billion to move drugs toward trials
First merged summary.
Isomorphic Labs raised $5 billion in a Series C, co-led by Greenoaks and Sequoia, to move its AI drug pipeline toward clinical trials.
Isomorphic Labs, the AI drug-discovery company spun out of Google DeepMind in 2021, raised $5 billion in a Series C to move candidates toward clinical trials. Greenoaks and Sequoia Capital co-led, with Andreessen Horowitz, Alphabet, and existing backers including GV, Capital G, Thrive Capital, MGX, Temasek, and the UK Sovereign AI Fund. Valuation was not disclosed; TechCrunch notes Bloomberg earlier reported a $50 billion target, while The Decoder says the company has no approved drug. The May 2026 round was $2.1 billion; new funds will advance IsoDDE, which Isomorphic says goes beyond AlphaFold 3, after preclinical oncology and immunology results and deals with Eli Lilly, Novartis, and Johnson & Johnson. Demis Hassabis leads the firm after leaving day-to-day DeepMind leadership in August 2026; TechCrunch says he became DeepMind chairman.
- Series C co-led by Greenoaks and Sequoia; Andreessen Horowitz and Alphabet participated.
- Follows a $2.1 billion round in May 2026; the new valuation was not disclosed.
- TechCrunch says Bloomberg earlier reported a $50 billion target valuation.
- Partners include Eli Lilly, Novartis, and Johnson & Johnson; no approved drug yet.
- Company says IsoDDE goes beyond AlphaFold 3 on binding and docking.
- Hassabis left day-to-day DeepMind leadership in August 2026.
Timeline
dated events in the reporting · oldest first- Nov 17, 2026Outlets report Isomorphic Labs' $5 billion Series C. · TechCrunch
What each outlet adds
beyond the shared facts- TechCrunchNames more backers, preclinical fields, chairman role, and Bloomberg’s figure.
- The DecoderNames IsoDDE, no approved drug, August exit, and Alphabet as investor.
Coverage
oldest first · one row per article · UTCIsomorphic Labs raises $5 billion to advance AI drug candidates
The Series C, co-led by Greenoaks and Sequoia, follows a $2.1 billion round in May; valuation was not disclosed.
Isomorphic Labs raises $5 billion in second mega-round in six months
The May 2026 round was $2.1 billion; funds target IsoDDE and clinical trials, with no approved drug yet.